The presence of antibodies against glutamic acid decarboxylase (GAD-abs) is related to a variety of clinical syndromes such as stiff-person syndrome (SPS), limbic encephalitis (LE), epilepsy, cerebellar ataxia, diabetes mellitus type I, and other autoimmune endocrine disorders (25). Here, GAD1 is linked to cerebellar ataxia.